최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.27 no.3, 2017년, pp.127 - 135
차승희 (부산대학교 약학대학) , 제남경 (부산대학교 약학대학)
Background: Kawasaki disease (KD) is an acute febrile, systemic vasculitis as a leading cause of acquired heart disease in children. Intravenous immunoglobulin G (IVIG) and aspirin are the standard initial therapy in the treatment of acute KD. The purpose of this study was to investigate drug utiliz...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
가와사키병이란? | 가와사키병(Kawasaki disease, KD)은 영유아에게서 주로 발병하는 급성 열성 전신성 혈관염으로, 6개월 이상, 5세 이하의 어린이에게서 주로 발병하고, 남아에게서 여아에 비해 1.4-1. | |
가와사키병은 주로 어느 연령에서 발생하는가? | 가와사키병(Kawasaki disease, KD)은 영유아에게서 주로 발병하는 급성 열성 전신성 혈관염으로, 6개월 이상, 5세 이하의 어린이에게서 주로 발병하고, 남아에게서 여아에 비해 1.4-1. | |
가와사키병을 치료하지 않으면 어떻게 되는가? | 6배 많은 환자가 보고되었다.1) 치료하지 않으면 15%-25%의 환자에서 관상동맥류(coronary artery aneurysm, CAA)나 관상동맥확장증(coronary artery dilation)과 같은 관상동맥이상(coronary abnormalities)이 발생할 수 있으며, 이는 허혈성 심장병, 심근경색 등을 유발하여 사망으로 이어질 수 있다.2)KD는 현재 소아의 후천적 심장질환을 일으키는 제 1의 원인 질환으로 알려져 있으며,3) 모든 인종에게서 발병하나 특히 아시아인에게서 유병률이 높은 것으로 알려져 있는데 그 중 일본이 1위, 한국, 대만이 각각 2위, 3위를 차지 한다. |
Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012;22:79-85.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71.
Abe J, Ebata R, Jibiki T, et al. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol 2008;122:1008-13.e8.
Park YW, Han JW, Hong YM, et al. Epidemiological features of Kawasaki disease in Korea, 2006-2008. Pediatr Int 2011;53:36-9.
Kim GB, Park S, Eun LY, et al. Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. Pediatr Infect Dis J 2017;36:482-5.
Research Committee of the Japanese Society of Pediatric C, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki D. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int 2014;56:135-58.
Zhou C, Huang M, Xie L, Shen J, Xiao T, Wang R. IVIG inhibits TNFalpha-induced MMP9 expression and activity in monocytes by suppressing NF-kappaB and P38 MAPK activation. Int J Clin Exp Pathol 2015;8:15879-86.
Matsuda A, Morita H, Unno H, et al. Anti-inflammatory effects of high-dose IgG on TNF-alpha-activated human coronary artery endothelial cells. Eur J Immunol 2012;42:2121-31.
Durongpisitkul K, Gururaj VJ. The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on the efficacy. Pediatrics 1995;96:1057.
Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017;135:e927-e99.
Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blindedendpoints trial. Lancet 2012;379:1613-20.
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12.
Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40.
Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9.
Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808-10.
Tremoulet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012;161:506-12.e1.
Akagi T, Kato H, Inoue O, et al. Salicylate treatment in Kawasaki disease: high dose or low dose? Eur J Pediatr 1991;150:642-6.
Saguil A, Fargo M, Grogan S. Diagnosis and management of kawasaki disease. Am Fam Physician 2015;91:365-71.
Park YW, Park IS, Kim CH, et al. Epidemiologic study of Kawasaki disease in Korea, 1997-1999: comparison with previous studies during 1991-1996. J Korean Med Sci 2002;17:453-6.
Park YW, Han JW, Park IS, et al. Epidemiologic picture of Kawasaki disease in Korea, 2000-2002. Pediatr Int 2005;47:382-7.
Ha S, Seo GH, Kim KY, et al. Epidemiologic Study on Kawasaki Disease in Korea, 2007-2014: Based on Health Insurance Review & Assessment Service Claims. J Korean Med Sci 2016;31:1445-9.
Kuo HC, Lo MH, Hsieh KS, et al. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease. PLoS One 2015;10:e0144603.
Baumer JH, Love SJ, Gupta A, et al. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006:Cd004175.
Hamada H. Aspirin treatment for patients with Kawasaki disease. Nihon Rinsho 2014;72:1612-6.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.